DK1457208T3 - Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer - Google Patents

Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer

Info

Publication number
DK1457208T3
DK1457208T3 DK04075804T DK04075804T DK1457208T3 DK 1457208 T3 DK1457208 T3 DK 1457208T3 DK 04075804 T DK04075804 T DK 04075804T DK 04075804 T DK04075804 T DK 04075804T DK 1457208 T3 DK1457208 T3 DK 1457208T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
testosterone levels
serum testosterone
achieving acceptable
reliably achieving
Prior art date
Application number
DK04075804T
Other languages
English (en)
Inventor
Doris Huebler
Sabine Fricke
Jan-Peter Ingwersen
Wilhelm Kuhnz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1457208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1457208T3 publication Critical patent/DK1457208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
DK04075804T 2003-03-14 2004-03-15 Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer DK1457208T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
EP04075804A EP1457208B9 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (1)

Publication Number Publication Date
DK1457208T3 true DK1457208T3 (da) 2006-12-11

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04075804T DK1457208T3 (da) 2003-03-14 2004-03-15 Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer

Country Status (40)

Country Link
US (2) US7718640B2 (da)
EP (2) EP1457208B9 (da)
JP (1) JP4680891B2 (da)
KR (2) KR20080096717A (da)
CN (2) CN101884639A (da)
AR (1) AR043603A1 (da)
AT (1) ATE336251T1 (da)
AU (1) AU2004218893B2 (da)
BR (2) BRPI0400214A8 (da)
CA (1) CA2518910C (da)
CL (1) CL2004000527A1 (da)
CO (1) CO5700724A2 (da)
CR (1) CR7999A (da)
CY (1) CY1105794T1 (da)
DE (1) DE602004001893T2 (da)
DK (1) DK1457208T3 (da)
EA (1) EA011568B1 (da)
EC (1) ECSP056095A (da)
ES (1) ES2271772T3 (da)
HK (1) HK1069325A1 (da)
HR (1) HRP20050781B1 (da)
IL (1) IL170473A (da)
IS (1) IS2565B (da)
JO (1) JO2505B1 (da)
ME (2) MEP14508A (da)
MX (1) MXPA04002395A (da)
NO (1) NO335179B1 (da)
NZ (1) NZ542321A (da)
PE (1) PE20041065A1 (da)
PL (1) PL1457208T3 (da)
PT (1) PT1457208E (da)
RS (1) RS51537B (da)
RU (2) RU2354381C2 (da)
SA (1) SA04250040B1 (da)
SI (1) SI1457208T1 (da)
TW (1) TWI345976B (da)
UA (1) UA82510C2 (da)
UY (1) UY28231A1 (da)
WO (1) WO2004080383A2 (da)
ZA (2) ZA200508313B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
AU2006236564B2 (en) * 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
US20120064166A1 (en) 2009-02-18 2012-03-15 Bayer Pharma Aktienesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
EA201791738A1 (ru) * 2012-05-09 2018-03-30 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции тестостерона
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
EP2953667B1 (en) * 2013-02-11 2019-10-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) * 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
AU2019396139A1 (en) * 2018-12-14 2021-07-15 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
HU228617B1 (en) * 1997-12-03 2013-04-29 Merial Llc Long acting injectable formulations containing hydrogenated castor oil
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
EP1087986B1 (en) 1998-06-19 2002-04-10 Akzo Nobel N.V. 7.alpha.-methyl 19-nortestosterone undecanoate with androgenic activity
ATE269708T1 (de) 1999-04-01 2004-07-15 Akzo Nobel Nv Formulierung enthaltend testosteonundecanoat und rizinusöl
ES2253423T3 (es) * 2000-08-23 2006-06-01 Akzo Nobel N.V. Formulacion de un ester de testosterona para uso humano.

Also Published As

Publication number Publication date
CA2518910A1 (en) 2004-09-23
EP1743646A3 (en) 2007-03-28
TWI345976B (en) 2011-08-01
ES2271772T3 (es) 2007-04-16
IS8069A (is) 2005-10-12
PT1457208E (pt) 2007-01-31
UA82510C2 (uk) 2008-04-25
HK1069325A1 (en) 2005-05-20
TW200511997A (en) 2005-04-01
NZ542321A (en) 2008-05-30
US7718640B2 (en) 2010-05-18
IL170473A (en) 2010-05-31
NO20054711L (no) 2005-12-13
US20090156564A1 (en) 2009-06-18
PL1457208T3 (pl) 2007-01-31
SI1457208T1 (sl) 2007-02-28
RU2005131724A (ru) 2006-05-10
MXPA04002395A (es) 2004-09-20
JP4680891B2 (ja) 2011-05-11
AU2004218893A1 (en) 2004-09-23
ME00149B (me) 2010-06-10
NO20054711D0 (no) 2005-10-13
BRPI0400214A (pt) 2005-02-09
KR100882378B1 (ko) 2009-02-05
EP1457208B9 (en) 2006-10-25
KR20050109561A (ko) 2005-11-21
SA04250040B1 (ar) 2008-01-07
EP1743646A2 (en) 2007-01-17
RU2007118196A (ru) 2008-11-27
UY28231A1 (es) 2004-11-08
BR122017008910A8 (pt) 2023-05-09
CA2518910C (en) 2009-09-08
WO2004080383A2 (en) 2004-09-23
ZA200508313B (en) 2007-04-25
BR122017008910A2 (da) 2005-02-09
RS20050702A (en) 2007-06-04
ECSP056095A (es) 2006-03-01
PE20041065A1 (es) 2005-02-24
EP1457208B1 (en) 2006-08-16
IS2565B (is) 2009-12-15
NO335179B1 (no) 2014-10-13
HRP20050781B1 (hr) 2015-04-10
US8338395B2 (en) 2012-12-25
EP1457208A1 (en) 2004-09-15
CN1761469A (zh) 2006-04-19
DE602004001893T2 (de) 2007-03-15
CY1105794T1 (el) 2011-02-02
CO5700724A2 (es) 2006-11-30
US20050032762A1 (en) 2005-02-10
JO2505B1 (en) 2009-10-05
EA011568B1 (ru) 2009-04-28
WO2004080383B1 (en) 2005-05-06
BRPI0400214A8 (pt) 2023-05-09
CN101884639A (zh) 2010-11-17
EA200501819A1 (ru) 2006-06-30
AR043603A1 (es) 2005-08-03
DE602004001893D1 (de) 2006-09-28
JP2006520377A (ja) 2006-09-07
RU2354381C2 (ru) 2009-05-10
CL2004000527A1 (es) 2005-02-18
MEP14508A (en) 2010-06-10
AU2004218893B2 (en) 2008-10-09
KR20080096717A (ko) 2008-10-31
RS51537B (en) 2011-06-30
CR7999A (es) 2006-05-29
HRP20050781A2 (en) 2005-10-31
CN1761469B (zh) 2019-05-17
ZA200700046B (en) 2008-04-30
WO2004080383A3 (en) 2005-03-31
ATE336251T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DK1457208T3 (da) Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
NO20032112L (no) Grensesnitt for visuale og scenegraf
DK1909764T3 (da) Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
AP2089A (en) Compositions and methods for combination antiviraltherapy
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1774566T3 (da) Sammensætninger til afgivelse af kviksölv og fremgangsmåde til fremstilling deraf
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
DE602004004267D1 (de) Formtrennmittelzusammensetzung und verfahren damit
HUP0303313D0 (en) Transdermal pharmaceutical compositions
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DE602005001520D1 (de) Zeiteinstellungssystem und Zeiteinstellungsverfahren
DK2110135T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
DK1587478T3 (da) Farmaceutisk sammensætning
DK1518827T3 (da) Krystalliseret IM-12-faststof og fremgangsmåde til fremstilling heraf
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
EP1765373A4 (en) OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
AU2003257109A8 (en) Compositions and methods for molecular biology